GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Shiller PE Ratio

IPA (ImmunoPrecise Antibodies) Shiller PE Ratio : (As of Dec. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ImmunoPrecise Antibodies Shiller PE Ratio Historical Data

The historical data trend for ImmunoPrecise Antibodies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Shiller PE Ratio Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ImmunoPrecise Antibodies Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ImmunoPrecise Antibodies's Shiller PE Ratio

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Shiller PE Ratio falls into.



ImmunoPrecise Antibodies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ImmunoPrecise Antibodies's E10 for the quarter that ended in Oct. 2024 is calculated as:

For example, ImmunoPrecise Antibodies's adjusted earnings per share data for the three months ended in Oct. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Oct. 2024 (Change)*Current CPI (Oct. 2024)
=-0.065/127.2847*127.2847
=-0.065

Current CPI (Oct. 2024) = 127.2847.

ImmunoPrecise Antibodies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.024 98.367 -0.031
201503 0.012 99.789 0.015
201506 0.012 100.500 0.015
201509 -0.004 100.421 -0.005
201512 -0.087 99.947 -0.111
201603 -0.011 101.054 -0.014
201606 -0.012 102.002 -0.015
201609 -0.005 101.765 -0.006
201701 -0.986 102.318 -1.227
201704 -0.115 103.029 -0.142
201707 -0.079 103.029 -0.098
201710 -0.079 103.424 -0.097
201801 -0.121 104.056 -0.148
201804 -0.157 105.320 -0.190
201807 -0.076 106.110 -0.091
201810 -0.077 105.952 -0.093
201901 -0.075 105.557 -0.090
201904 -0.224 107.453 -0.265
201907 -0.114 108.243 -0.134
201910 -0.076 107.927 -0.090
202001 -0.038 108.085 -0.045
202004 -0.050 107.216 -0.059
202007 -0.030 108.401 -0.035
202010 -0.023 108.638 -0.027
202101 -0.063 109.192 -0.073
202104 -0.240 110.851 -0.276
202107 -0.136 112.431 -0.154
202110 -0.209 113.695 -0.234
202201 -0.158 114.801 -0.175
202204 -0.182 118.357 -0.196
202207 -0.294 120.964 -0.309
202210 -0.219 121.517 -0.229
202301 -0.142 121.596 -0.149
202304 -0.156 123.571 -0.161
202307 -0.106 124.914 -0.108
202310 -0.073 125.310 -0.074
202401 -0.082 125.072 -0.083
202404 -0.512 126.890 -0.514
202407 -0.109 128.075 -0.108
202410 -0.065 127.285 -0.065

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ImmunoPrecise Antibodies  (NAS:IPA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ImmunoPrecise Antibodies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.

ImmunoPrecise Antibodies Headlines

From GuruFocus